0.54
+0.0329(+6.53%)
Currency In USD
| Previous Close | 0.5 |
| Open | 0.49 |
| Day High | 0.57 |
| Day Low | 0.48 |
| 52-Week High | 1.07 |
| 52-Week Low | 0.28 |
| Volume | 9.67M |
| Average Volume | 3.65M |
| Market Cap | 122.6M |
| PE | -2.07 |
| EPS | -0.26 |
| Moving Average 50 Days | 0.41 |
| Moving Average 200 Days | 0.63 |
| Change | 0.03 |
If you invested $1000 in Vaxart, Inc. (VXRT) 10 years ago, it would be worth $23.81 as of June 13, 2025 at a share price of $0.537. Whereas If you bought $1000 worth of Vaxart, Inc. (VXRT) shares 5 years ago, it would be worth $218.29 as of June 13, 2025 at a share price of $0.537.
For more details, use our stock calculator to calculate how much you would've made investing different amounts on specific dates.
Vaxart Reports Positive Clinical Data Demonstrating that its Second-Generation Vaccine Technology Produces Much Stronger Antibody Responses than its First-Generation Technology
GlobeNewswire Inc.
Jun 11, 2025 11:30 AM GMT
- Second-generation norovirus constructs produce statistically significant increases in GI.1 and GII.4 norovirus blocking antibodies (141% and 94%, respectively) compared with first-generation constructs, supporting potential for improved protection
Vaxart to Host Conference Call on June 11 at 8:30 AM ET to Discuss Topline Results from Its Phase I Norovirus Trial
GlobeNewswire Inc.
Jun 10, 2025 8:47 PM GMT
SOUTH SAN FRANCISCO, Calif., June 10, 2025 (GLOBE NEWSWIRE) -- Vaxart, Inc. (NASDAQ: VXRT), a clinical-stage biotechnology company developing a range of oral recombinant pill vaccines based on its proprietary delivery platform, today announced it w
Vaxart to Participate at the Jefferies Global Healthcare Conference on June 5, 2025
GlobeNewswire Inc.
May 29, 2025 8:05 PM GMT
SOUTH SAN FRANCISCO, Calif., May 29, 2025 (GLOBE NEWSWIRE) -- Vaxart, Inc. (NASDAQ: VXRT), a clinical-stage biotechnology company developing a range of oral recombinant pill vaccines based on its proprietary delivery platform, today announced that